{
    "organizations": [],
    "uuid": "25ac941aab4bba86db47eb34e2836ed5430429ed",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-cipher-pharmaceuticals-q1-loss-per/brief-cipher-pharmaceuticals-q1-loss-per-share-0-04-from-continuing-operations-idUSASC0A1CD",
    "ord_in_thread": 0,
    "title": "Cipher Pharmaceuticals Q1 Loss Per Share $0.04 From Continuing Operations",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " Updated 8 minutes ago BRIEF-Cipher Pharmaceuticals Q1 Loss Per Share $0.04 From Continuing Operations Cipher Pharmaceuticals Inc: * Q1 REVENUE $4.6 MILLION VERSUS $8.1 MILLION\n* EXPECTS TO ADD SIX NEW PRODUCTS FROM ITS EXISTING PIPELINE TO ITS CANADIAN COMMERCIAL PORTFOLIO IN 2018 AND 2019\n* CONTINUES TO PURSUE NEW IN-LICENSING OPPORTUNITIES AND ACQUISITIONS TO FURTHER EXPAND ITS NEAR-TERM PRODUCT PIPELINE\n* EXPECTS ITS GLOBAL LICENSING BUSINESS TO PROVIDE A “SOLID BASE” OF HIGH-MARGIN ROYALTY REVENUE IN 2018 ",
    "published": "2018-05-10T19:13:00.000+03:00",
    "crawled": "2018-05-10T14:25:21.022+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "updated",
        "minute",
        "ago",
        "pharmaceutical",
        "q1",
        "loss",
        "per",
        "share",
        "continuing",
        "operation",
        "cipher",
        "pharmaceutical",
        "inc",
        "q1",
        "revenue",
        "million",
        "versus",
        "million",
        "expects",
        "add",
        "six",
        "new",
        "product",
        "existing",
        "pipeline",
        "canadian",
        "commercial",
        "portfolio",
        "continues",
        "pursue",
        "new",
        "opportunity",
        "acquisition",
        "expand",
        "product",
        "pipeline",
        "expects",
        "global",
        "licensing",
        "business",
        "provide",
        "solid",
        "base",
        "royalty",
        "revenue"
    ]
}